Rosetta Genomics Plans to Raise $6.6M in Direct Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Thursday it has entered into definitive agreements with investors to raise $6.6 million in a direct offering.

The agreement calls for investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share. The offering is expected to close on or about May 31, the Israel-based molecular diagnostic company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.